Table of Contents
1 Report Overview
1.1 Research Scope
1.2 Top Human Coagulation Factor VIII Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Human Coagulation Factor VIII Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 Recombinant Factor VIII
1.3.3 Plasma-derived Factor VIII
1.4 Market Segment by Application
1.4.1 Global Human Coagulation Factor VIII Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Hemophilia A
1.4.3 Spontanous / Trauma
1.4.4 Surgical
1.4.5 Other
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Human Coagulation Factor VIII Revenue (2015-2026)
2.1.1 Global Human Coagulation Factor VIII Revenue (2015-2026)
2.1.2 Global Human Coagulation Factor VIII Sales (2015-2026)
2.2 Human Coagulation Factor VIII Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Human Coagulation Factor VIII Sales by Regions (2015-2020)
2.2.2 Global Human Coagulation Factor VIII Revenue by Regions (2015-2020)
2.3 Global Top Human Coagulation Factor VIII Regions (Countries) Ranking by Market Size
2.4 Human Coagulation Factor VIII Industry Trends
2.4.1 Human Coagulation Factor VIII Market Top Trends
2.4.2 Market Drivers
2.4.3 Human Coagulation Factor VIII Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Human Coagulation Factor VIII Players: Views for Future
3 Competitive Landscape by Manufacturers
3.1 Global Top Human Coagulation Factor VIII Manufacturers by Sales (2015-2020)
3.1.1 Global Human Coagulation Factor VIII Sales by Manufacturers (2015-2020)
3.1.2 Global Human Coagulation Factor VIII Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Human Coagulation Factor VIII Sales in 2019
3.2 Global Top Manufacturers Human Coagulation Factor VIII by Revenue
3.2.1 Global Human Coagulation Factor VIII Revenue by Manufacturers (2015-2020)
3.2.2 Global Human Coagulation Factor VIII Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Human Coagulation Factor VIII Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Coagulation Factor VIII as of 2019)
3.4 Global Human Coagulation Factor VIII Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Human Coagulation Factor VIII Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Human Coagulation Factor VIII Market
3.7 Key Manufacturers Human Coagulation Factor VIII Product Offered
3.8 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Human Coagulation Factor VIII Historic Market Review by Type (2015-2020)
4.1.2 Global Human Coagulation Factor VIII Sales Market Share by Type (2015-2020)
4.1.3 Global Human Coagulation Factor VIII Revenue Market Share by Type (2015-2020)
4.1.4 Human Coagulation Factor VIII Price by Type (2015-2020)
4.1 Global Human Coagulation Factor VIII Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Human Coagulation Factor VIII Sales Forecast by Type (2021-2026)
4.2.3 Global Human Coagulation Factor VIII Revenue Forecast by Type (2021-2026)
4.2.4 Human Coagulation Factor VIII Price Forecast by Type (2021-2026)
5 Global Human Coagulation Factor VIII Market Size by Application
5.1 Global Human Coagulation Factor VIII Historic Market Review by Application (2015-2020)
5.1.2 Global Human Coagulation Factor VIII Sales Market Share by Application (2015-2020)
5.1.3 Global Human Coagulation Factor VIII Revenue Market Share by Application (2015-2020)
5.1.4 Human Coagulation Factor VIII Price by Application (2015-2020)
5.2 Global Human Coagulation Factor VIII Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Human Coagulation Factor VIII Sales Forecast by Application (2021-2026)
5.2.3 Global Human Coagulation Factor VIII Revenue Forecast by Application (2021-2026)
5.2.4 Human Coagulation Factor VIII Price Forecast by Application (2021-2026)
6 North America
6.1 North America Human Coagulation Factor VIII Breakdown Data by Company
6.2 North America Human Coagulation Factor VIII Breakdown Data by Type
6.3 North America Human Coagulation Factor VIII Breakdown Data by Application
6.4 North America Human Coagulation Factor VIII Breakdown Data by Countries
6.4.1 North America Human Coagulation Factor VIII Sales by Countries
6.4.2 North America Human Coagulation Factor VIII Revenue by Countries
6.4.3 U.S.
6.4.4 Canada
7 Europe
7.1 Europe Human Coagulation Factor VIII Breakdown Data by Company
7.2 Europe Human Coagulation Factor VIII Breakdown Data by Type
7.3 Europe Human Coagulation Factor VIII Breakdown Data by Application
7.4 Europe Human Coagulation Factor VIII Breakdown Data by Countries
7.4.1 Europe Human Coagulation Factor VIII Sales by Countries
7.4.2 Europe Human Coagulation Factor VIII Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
8 Asia Pacific
8.1 Asia Pacific Human Coagulation Factor VIII Breakdown Data by Company
8.2 Asia Pacific Human Coagulation Factor VIII Breakdown Data by Type
8.3 Asia Pacific Human Coagulation Factor VIII Breakdown Data by Application
8.4 Asia Pacific Human Coagulation Factor VIII Breakdown Data by Regions
8.4.1 Asia Pacific Human Coagulation Factor VIII Sales by Regions
8.4.2 Asia Pacific Human Coagulation Factor VIII Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam
9 Latin America
9.1 Latin America Human Coagulation Factor VIII Breakdown Data by Company
9.2 Latin America Human Coagulation Factor VIII Breakdown Data by Type
9.3 Latin America Human Coagulation Factor VIII Breakdown Data by Application
9.4 Latin America Human Coagulation Factor VIII Breakdown Data by Countries
9.4.1 Latin America Human Coagulation Factor VIII Sales by Countries
9.4.2 Latin America Human Coagulation Factor VIII Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Human Coagulation Factor VIII Breakdown Data by Type
10.2 Middle East and Africa Human Coagulation Factor VIII Breakdown Data by Application
10.3 Middle East and Africa Human Coagulation Factor VIII Breakdown Data by Countries
10.3.1 Middle East and Africa Human Coagulation Factor VIII Sales by Countries
10.3.2 Middle East and Africa Human Coagulation Factor VIII Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E
11 Company Profiles
11.1 Shire (Baxter)
11.1.1 Shire (Baxter) Corporation Information
11.1.2 Shire (Baxter) Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Shire (Baxter) Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Shire (Baxter) Human Coagulation Factor VIII Products and Services
11.1.5 Shire (Baxter) SWOT Analysis
11.1.6 Shire (Baxter) Recent Developments
11.2 Bayer
11.2.1 Bayer Corporation Information
11.2.2 Bayer Business Overview and Total Revenue (2019 VS 2018)
11.2.3 Bayer Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.2.4 Bayer Human Coagulation Factor VIII Products and Services
11.2.5 Bayer SWOT Analysis
11.2.6 Bayer Recent Developments
11.3 CSL
11.3.1 CSL Corporation Information
11.3.2 CSL Business Overview and Total Revenue (2019 VS 2018)
11.3.3 CSL Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.3.4 CSL Human Coagulation Factor VIII Products and Services
11.3.5 CSL SWOT Analysis
11.3.6 CSL Recent Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Business Overview and Total Revenue (2019 VS 2018)
11.4.3 Pfizer Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.4.4 Pfizer Human Coagulation Factor VIII Products and Services
11.4.5 Pfizer SWOT Analysis
11.4.6 Pfizer Recent Developments
11.5 Grifols
11.5.1 Grifols Corporation Information
11.5.2 Grifols Business Overview and Total Revenue (2019 VS 2018)
11.5.3 Grifols Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.5.4 Grifols Human Coagulation Factor VIII Products and Services
11.5.5 Grifols SWOT Analysis
11.5.6 Grifols Recent Developments
11.6 Biogen
11.6.1 Biogen Corporation Information
11.6.2 Biogen Business Overview and Total Revenue (2019 VS 2018)
11.6.3 Biogen Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.6.4 Biogen Human Coagulation Factor VIII Products and Services
11.6.5 Biogen SWOT Analysis
11.6.6 Biogen Recent Developments
11.7 Octapharma
11.7.1 Octapharma Corporation Information
11.7.2 Octapharma Business Overview and Total Revenue (2019 VS 2018)
11.7.3 Octapharma Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.7.4 Octapharma Human Coagulation Factor VIII Products and Services
11.7.5 Octapharma SWOT Analysis
11.7.6 Octapharma Recent Developments
11.8 NovoNordisk
11.8.1 NovoNordisk Corporation Information
11.8.2 NovoNordisk Business Overview and Total Revenue (2019 VS 2018)
11.8.3 NovoNordisk Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.8.4 NovoNordisk Human Coagulation Factor VIII Products and Services
11.8.5 NovoNordisk SWOT Analysis
11.8.6 NovoNordisk Recent Developments
11.9 Greencross
11.9.1 Greencross Corporation Information
11.9.2 Greencross Business Overview and Total Revenue (2019 VS 2018)
11.9.3 Greencross Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.9.4 Greencross Human Coagulation Factor VIII Products and Services
11.9.5 Greencross SWOT Analysis
11.9.6 Greencross Recent Developments
11.10 Kedrion
11.10.1 Kedrion Corporation Information
11.10.2 Kedrion Business Overview and Total Revenue (2019 VS 2018)
11.10.3 Kedrion Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.10.4 Kedrion Human Coagulation Factor VIII Products and Services
11.10.5 Kedrion SWOT Analysis
11.10.6 Kedrion Recent Developments
11.11 BPL
11.11.1 BPL Corporation Information
11.11.2 BPL Business Overview and Total Revenue (2019 VS 2018)
11.11.3 BPL Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.11.4 BPL Human Coagulation Factor VIII Products and Services
11.11.5 BPL SWOT Analysis
11.11.6 BPL Recent Developments
11.12 Hualan Bio
11.12.1 Hualan Bio Corporation Information
11.12.2 Hualan Bio Business Overview and Total Revenue (2019 VS 2018)
11.12.3 Hualan Bio Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.12.4 Hualan Bio Human Coagulation Factor VIII Products and Services
11.12.5 Hualan Bio SWOT Analysis
11.12.6 Hualan Bio Recent Developments
11.13 RAAS
11.13.1 RAAS Corporation Information
11.13.2 RAAS Business Overview and Total Revenue (2019 VS 2018)
11.13.3 RAAS Human Coagulation Factor VIII Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.13.4 RAAS Human Coagulation Factor VIII Products and Services
11.13.5 RAAS SWOT Analysis
11.13.6 RAAS Recent Developments
12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Human Coagulation Factor VIII Sales Channels
12.2.2 Human Coagulation Factor VIII Distributors
12.3 Human Coagulation Factor VIII Customers
13 Estimates and Projections by Regions (2021-2026)
13.1 Global Human Coagulation Factor VIII Sales Forecast (2021-2026)
13.1.1 Global Human Coagulation Factor VIII Sales Forecast by Regions (2021-2026)
13.1.2 Global Human Coagulation Factor VIII Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Human Coagulation Factor VIII Sales Forecast (2021-2026)
13.2.2 North America Human Coagulation Factor VIII Revenue Forecast (2021-2026)
13.2.3 North America Human Coagulation Factor VIII Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Human Coagulation Factor VIII Sales Forecast (2021-2026)
13.3.2 Europe Human Coagulation Factor VIII Revenue Forecast (2021-2026)
13.3.3 Europe Human Coagulation Factor VIII Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Human Coagulation Factor VIII Sales Forecast (2021-2026)
13.4.2 Asia Pacific Human Coagulation Factor VIII Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Human Coagulation Factor VIII Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Human Coagulation Factor VIII Sales Forecast (2021-2026)
13.5.2 Latin America Human Coagulation Factor VIII Revenue Forecast (2021-2026)
13.5.3 Latin America Human Coagulation Factor VIII Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Human Coagulation Factor VIII Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Human Coagulation Factor VIII Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Human Coagulation Factor VIII Size Forecast by County (2021-2026)
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
【掲載企業】
Shire (Baxter)、Bayer、CSL、Pfizer、Grifols、Biogen、Octapharma、NovoNordisk、Greencross、Kedrion、BPL、Hualan Bio、RAAS
【免責事項】
https://www.globalresearch.jp/disclaimer